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STIMULI-RESPONSIVE HYDROGEL 
MICRODOMES INTEGRATED WITH 
GENETICALLY ENGINEERED PROTEINS 
FOR HIGH-THROUGHPUT SCREENING OF 
PHARMACEUTICALS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of application 
Ser. No. 09/905,041 ?led Jul. 13, 2001, published Jun. 6, 2002 
as Publication No. US 2002/0068295, noW abandoned Which 
claims priority to US. Provisional Application Ser. No. 
60/218,036, ?led Jul. 13, 2000, Which is incorporated herein 
by reference. 
GOVERNMENT INTEREST IN THE INVENTION 
This invention Was made With Government support under 
Grant No. EB003072 aWarded by the National Institutes of 
Health. The Government may have certain rights in this 
invention. 
FIELD OF THE INVENTION 
This invention is directed to a stimuli-responsive hydro gels 
integrated With genetically engineered proteins for use for 
high-throughput screening of analytes as Well as for use as an 
actuator and biosensor. 
BACKGROUND OF THE INVENTION 
Proteins and DNA are information rich molecules With 
structural and electrical properties Which make their incorpo 
ration into the human manufacturing arsenal an attractive 
proposition. Several microstructures using oligonucleotides 
as building blocs have been demonstrated (N. C. Seeman, 
Ann. Rev. Biophys. Biomol. Slrua, vol. 27, pp. 225, 1998; B. 
Winfree, F. Liu, L. WenZler, and N. C. Seeman, Nature, vol. 
394, pp. 539, 1998.), and many particles/objects have been 
derivatiZed With DNA strands or oligonucleotides (R. Bashir, 
“DNA-Mediated Arti?cial Nano-Bio-Structures: State of the 
Art Future Directions,” Superlallice and Microslruclures, 
vol. 29, pp. 1-16, 2001 .) Short strands ofDNA, also knoWn as 
aptamers have been suggested as a tool in DNA mediated self 
assembly of micro components into larger subassemblies or 
onto a PC board (C. F. Edman, C. Gurtner, R. E. Formosa, J. 
J. Coleman, and M. J. Heller, “Electric-Field-Directed Pick 
and-Place Assembly,” HDI, vol. October, pp. 30-35, 2000; C. 
F. Edman, R. B. SWint, C. Gurtner, R. B. Formosa, S. D. Roh, 
K. B. Lee, P. D. SWanson, D. B. Ackley, J. J. Coleman, and M. 
J. Heller, “Electric Field Directed Assembly of an InGaAs 
LED onto Silicon Circuitry,”lEEE Pholonics Tech. LeZL, vol. 
12, pp. 1198-1200, 2000; C. A. Mirkin, R. L. Letsinger, R. C. 
Mucic, and J. J. Storhoff, Nature, vol. 382, pp. 607, 1996.). 
Proteins have also been used in a Wide variety of microstruc 
tures With motor proteins, perhaps the most studied example. 
The ?rst examples of combinations of proteins With micro 
machined structures Were realiZed recently. 
The combination of the natural biopolymers With micro 
electromechanical systems (MEMS) and nanoelectrome 
chanical systems (NEMS) promises the advent of a totally 
neW class of sensors and actuators With applications in drug 
delivery, diagnostics, biocompatible surfaces, prosthetics and 
many other ?elds. 
Advanced biomaterials are of high importance in biomedi 
cine, and especially, in neW-generation medical devices and 
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implants. These materials can be used in a multitude of bio 
medical applications related to the treatment and manage 
ment of disease. Currently, there are a limited number of 
biomaterials that are suitable for biomedical applications. For 
example, the materials need to be prepared and perform in a 
reproducible, accurate, selective, and sensitive manner, and 
they need to be amenable to integration into devices that can 
be employed in a variety of applications (e.g., biosensors, 
delivery systems, diagnostic and high throughput screening 
platforms, etc.), those being in vitro or in vivo. 
Conventional drug delivery methods incorporate tablets, 
capsules, and emulsions that have di?icult-to-control release 
rates and nonspeci?c delivery sites. An ideal drug delivery 
system Would be able to provide a speci?c release pro?le in 
response to an external stimulus. Traditional drug release 
tablets cannot control the amount of drug released ef?ciently. 
The drug concentration may extend beyond the therapeutic 
WindoW risking ineffectiveness or toxicity. Over the last tWo 
decades a neW type of drug delivery, controlled drug delivery 
(also referred to as controlled release), has evolved in order to 
optimiZe drug therapy When conventional drug delivery 
methods, such as tablets, pills, solutions, and suspensions, are 
inadequate. Controlled release is most commonly achieved 
by incorporating (or “encapsulating”) drugs in either biode 
gradable or nondegradable polymers, Which can control the 
release of the drug to the body over speci?c times ranging 
from a day to several years. A major limitation in the useful 
ness of controlled release systems is that conventional 
implantable devices release drugs at a predetermined rate(s). 
HoWever, in certain instances, it is required that drugs are 
administered either at a life-threatening moment or repeat 
edly at a certain critical time of day. The latter is a requirement 
in the design of controlled release systems for certain disease 
states, such as diabetes, heart disease, and hormonal disor 
ders. Drug delivery technology could be brought to the next 
level if We could understand hoW to prepare “intelligent” 
polymers that are “responsive” to the patient’s therapeutic 
requirements and deliver certain amount of a drug in response 
to a biological stimulus. 
A multitude of binding proteins exist for a variety of 
ligands such as sugars, amino acids, peptides, and inorganic 
ions. Likewise, enZymes are another class of proteins that 
undergo conformational changes as they catalyZe a speci?c 
reaction. Enzymes can serve as biorecognition elements for 
substrates, inhibitors, and allosteric effectors. These binding 
proteins and enZymes come from a range of organisms, some 
of Which groW under extreme environmental conditions. 
These organisms, termed extremophiles, have adapted to 
prosper at temperatures as high as that of boiling Water in 
thermal vents (hyperthermophiles) or as loW as that of ice 
bergs (psychrophiles). Unlike conventional of-the-shelf pro 
teins that come from organisms that groW at 20 to 370 C., and 
are non-functional at temperatures above or beloW this range, 
proteins from extremophiles can perform under severe con 
ditions. 
There are a feW examples in the literature Where proteins 
have been integrated into materials capable of displaying a 
signi?cant change in their characteristics in response to a 
stimulus. Most of these examples refer to the development of 
What are knoWn as “smart” polymers or devices intended for 
use in delivery systems. The “smart” polymers can be pre 
pared so that they are responsive to the individual patient’s 
therapeutic requirements and deliver certain amount of a drug 
in response to a biological stimulus. 
The conventional “smart” polymer based on antigen-anti 
body interactions shoWed promise for responsive drug deliv 
ery. A semi-interpenetrating hydrogel polymer netWork Was 
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prepared consisting of a polymer containing rabbit antibody 
(IgG) and goat anti-rabbit IgG as the antigen. This hydrogel is 
able to sWell in the presence of free antigen, rabbit IgG, due to 
competition betWeen free antigen and polymer-immobilized 
antigen. Upon removal of free antigen, the hydrogel shrinks, 
thus, exhibiting a reversible sWelling and shrinking behavior, 
Which Was dependent on free antigen concentration. 
There is a need for high-throughput screening devices in 
the pharmaceutical industry for rapid and accurate selection 
of possible drug candidates that are most active or effective. 
Currently, laborious combinatorial techniques are used to 
screen analytes. These techniques are taxing on both time and 
resources. UtiliZing a stimuli-responsive hydrogel array of 
microdomes of the present invention, alloWs for ef?cient 
screening of these compounds in minutes. 
This invention is directed to a highly sensitive responsive 
system for detecting analytes based on the induced confor 
mational change upon binding of the analytes to their respec 
tive binding proteins. The system can also be useful as an 
actuator or biosensor. The conventional hydrogel synthesis 
does not permit exact control of three-dimensional structure 
of the hydrogel microdome, making it dif?cult to predict 
hydrogel performance and hindering the potential for bio 
medical applications. To overcome this problem, this inven 
tion includes the preparation of a hybrid hydrogel that incor 
porates a biopolymer Within its structure. The biopolymer can 
be a monomer or multimer. This hybrid hydrogel has precise 
and reproducible sWelling characteristics. 
SUMMARY OF THE INVENTION 
The present invention provides for a stimuli-responsive 
hydrogel netWork integrating a biopolymer. The hydrogel 
netWork can be formed into microdomes that undergo a phase 
transition. In response to a stimulus or the presence of an 
analyte, the hydrogel microdome sWells. The hydrogel 
microdome can then undergo a reversible sWelling of the 
netWork in response to an external stimulus. 
The stimuli-responsive hydrogels of the present invention 
have an integrated biological recognition element that pro 
vides excellent selectivity for ligands of interest. The stimuli 
sensitive hydrogels reproducibly sWell upon addition of a 
target molecule, Which controls the release of a biomolecule. 
The amount of sWelling of these hydrogels Was attributed to 
release of non-covalent bonds Within the polymer netWork. 
The stimuli-responsive hydrogel of the present invention 
has a multiple ligand response With precise three-stage active 
sWelling characteristics achieved by coupling ligand sensing 
With the conformational change of the site-speci?cally immo 
biliZed biological recognition element. In addition, the extent 
of actuation observed is proportional to the concentration of 
ligand present. 
The stimuli-responsive hydrogels of the present invention 
are useful for high-throughput screening of analytes as Well 
as for use as an actuator or a biosensor. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention may be more readily understood by 
reference to the folloWing draWings Wherein: 
FIG. 1 is an illustration of calmodulin undergoing a con 
formational change When it binds to Ca++ and phenothiaZine; 
FIG. 2 shoWs the construction of plasmid pSDl009 in the 
preparation of a dimer of calmodulin; 
FIG. 3 illustrates the modi?cation of calmodulin and a 
phenothiaZine, and the synthesis of a protein hydrogel; 
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FIG. 4 is an illustration of hydrogel deposited on a metal 
electrode (e.g., Pt) as an actuator, shoWing Water hydrolysis 
and reversible sWelling and shrinking of the hydrogel; 
FIG. 5 illustrates (a) the “dumbbell” conformation of calm 
odulin containing Ca++, (b) the conformation of calmodulin 
in the presence of a phenothiaZine, and (c) the conformation 
of calmodulin in the presence of ethylene glycol-bis([3-ami 
noethyl ether)-N',N',N',N'-tetraacetic acid (EGTA); 
FIG. 6 illustrates the hydrogel structure of the original and 
sWollen states of the calmodulin integrated hydrogel in the 
presence of chlorpromaZine; 
FIG. 7 graphically illustrates the sWelling and shrinking of 
the camodulin protein integrated hydrogel in the presence and 
absence of chlorpromaZine through 5 cycles; 
FIG. 8 is a graph shoWing the experimental response of a 
camodulin monomer to chlorpromaZine, and the theoretical 
as Well as the experimental response of a camodulin dimer to 
chlorpromaZine; 
FIG. 9 shoWs SEM images (a) and (c) depicting calmodulin 
protein-integrated hydrogel in the original (shrunken) and 
sWollen states, respectively, (b) and (d) shoWs the correspond 
ing ellipsoid surface maps of microdomes (a) and (c), respec 
tively, formed of a calmodulin protein integrated hydrogel; 
FIG. 10 shoWs hydrogel microdomes in the original 
(shrunken) state and the sWollen state in response to the 
presence of chlorpromaZine; 
FIG. 11 shoWs ellipsoid surface map of a hydrogel micro 
dome; 
FIG. 12 illustrates graphically the sWelling pro?les of 
stimuli-responsive hydrogel microdomes; 
FIGS. 13(a) and 13(b) are plan and side vieWs, respec 
tively, of an array of microdomes on a substrate; 
FIG. 14 illustrates the apparatus used to measure the dif 
fraction off the top of a hydrogel microdome; 
FIG. 15 are images of the light diffraction pattern off the 
unsWollen microdome and the interference pattern generated 
off a sWollen microdome; 
FIG. 16 graphically illustrates the sWelling kinetics of the 
hydrogel microdomes; 
FIG. 17 graphically illustrates the response of the protein 
and phenyl integrated hydrogel in the presence of chlorpro 
maZine; 
FIG. 18 is a schematic representing a dimer of calmodulin 
changing conformation in the presence of a stimulus; 
FIG. 19 is an illustration of an example of polymer proteins 
functioning as sensors and actuators; and 
FIG. 20 is an illustration of Wiring a multimeric biopoly 
mer (DNA in this case) With a redox polymer to an underlying 
conductive microelectrode Where the DNA is anchored to the 
redox material via a biotin-streptavidin linkage. 
DETAILED DESCRIPTION OF THE INVENTION 
This invention is directed to a stimuli-responsive hydrogel 
that can be used as used as a high-throughput screening 
device of analytes and pharmaceuticals. The hydro gel is in the 
form of microdomes comprising a hydrogel having integrated 
therein, genetically engineered proteins. In particular, the 
stimuli-responsive hydro gel has a three dimensional open cell 
lattice structure that integrates a biological recognition ele 
ment and a biomolecule ligand. 
A ?ne-tuned response is achieved by creating three speci?c 
sWelling stages of the protein-integrated hydrogel, Which 
offers added control over the conventional tWo-stage hydro 
gel sWelling illustrated in FIG. 1. In particular, the stimuli 
responsive hydrogel of the present invention has integrated 
therein a biopolymer that produces a response in the presence 
US 7,625,951 B2 
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of a protein-binding ligand. The biopolymer can be a mono 
mer or multimer. The response of the stimuli-sensitive hydro 
gel is a direct result of speci?c binding events and concomi 
tant conformational changes of the integrated protein 
occurring simultaneously Within the hydrogel. The advanced 
biomaterials have tailored response characteristics. 
Micromechanical devices and biosensors, such as MEMS 
and NEMS, i.e., systems that comprise a machined micro 
structure or nanostructure, respectively, such as for example a 
chip comprising a polysilicon membrane for pressure sens 
ing, contain the multimeric biopolymers of the present inven 
tion. Such devices can comprise a hydrogel or a redox poly 
mer. The device further comprises both a redox polymer and 
a hydrogel. MEMS and NEMS systems further comprise an 
electronic component Which may either be part of the micro 
structure or nanostructure or in hybrid fashion coupled 
thereto. 
As used herein, the term “hydrogel” refers to a polymer 
that takes on at least 30% of its Weight in Water. 
As used herein the term “sensor” or “biosensor” refers to a 
multimeric biopolymer Which gives off a detectable signal, 
such as for example, a ?uorescent signal in response to an 
analyte or the sWelling response of a hydrogel. 
As used herein the term “actuator” refers to a multimeric 
biopolymer that (a) exhibits a mechanical response When 
exposed to an analyte or (b) causes another substance, such as 
for example a hydrogel, to exhibit a mechanical response 
When the multimeric biopolymer is exposed to an analyte. 
As used herein the term “biopolymer” refers to a biomol 
ecule capable of responding to a change in its microenviron 
ment. Examples of biopolymers are proteins, polypeptides, 
and nucleic acid molecules. One Way in Which a biopolymer 
can respond to a change in its microenvironment is by chang 
ing its conformation. For example, one Way in Which a protein 
can change conformation is by unfolding, totally or in part 
(i.e., local areas of the protein can unfold). Examples of 
microenvironmental changes that can cause the biopolymers 
to respond include such things as an increase or decrease in 
pH or an increase or decrease in the concentration of speci?c 
analyte(s). One speci?c example of a biopolymer is calmodu 
lin (CaM). The speci?c analyte bound by CaM are calcium 
ions and the anti-psychotic phenothiaZine class of drugs, 
Which include chlorpromaZine, trioridaZine, tri?uoperaZine 
and perphenaZine. CaM molecules respond to binding cal 
cium by changing conformation. In addition, When phenothi 
aZines are present, CaM responds by undergoing additional 
change in conformation. 
In one aspect, a synthetic multimeric biopolymer can com 
prise at least tWo, preferably a plurality, of monomeric units 
of a biopolymer. At least one of the monomeric units, and 
preferably a plurality of the monomeric units, comprise one 
or more binding regions that bind to an analyte or a pharma 
ceutical compound. The analyte may be a biochemical that is 
found in an organism (e.g., bacteria, yeast, animals, humans, 
plants, etc.), such as for example a sugar, a protein, a nucleic 
acid, a hormone, a vitamin, or a co-factor. The analyte may 
also be an ion such as for example a hydrogen ion, a hydroxyl 
ion, an oxyanion (e.g., phosphate, sulfate, etc.) or a cation 
(e.g., calcium ion, etc.). The bonds that form betWeen the 
analyte and the binding region include all chemical bonds 
except covalent bonds. Examples of such chemical bonds are 
ionic bonds, hydrogen bonds, hydrophobic interactions and 
van der Waals forces. Further, the analyte may be molecules 
such as drugs, vitamins, hormones, antibodies, enZymes, co 
factors, nucleotides, proteins and so forth. 
The monomeric unit is selected from the group consisting 
of a full-length protein, a polypeptide Which is a fragment of 
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a full-length protein, a nucleic acid molecule, Which is pref 
erably an aptamer, a peptide nucleic acid. The monomeric 
units may be the same or different. 
The multimeric polymer undergoes a detectable conforma 
tional change in response to exposure to the analyte. Such a 
composition is a structurally linked multimer of biomolecules 
(e.g., multimers composed of linked proteins, DNA, RNA, 
peptide nucleic acids, etc.), and combinations thereof. When 
disposed Within a device, such as for example a polymeric 
drug delivery device or a machined microstructure or nano 
structure, the conformationally-reactive multimeric biopoly 
mer can be used to open or close a channel, either directly or 
indirectly. As used herein, this response to the analyte is 
referred to as an actuating event. 
Exposure of the multimeric biopolymer to the analyte 
causes the multimeric biopolymer to emit a detectable signal, 
such as for example a ?uorescent signal. Examples of such 
detectable signals are ?uorescent signals, an optical signals, 
electrochemical signals, pressure changes, changes in dielec 
tric constant, mass changes, volume changes, and tempera 
ture changes. Such multimeric biopolymers can be used as a 
sensor, particularly Within a MEMS or NEMS to detect the 
presence of the analyte and to generate a signal Which is 
transmitted to a transducer. 
An example of a multimeric biopolymer of the present 
invention is a dimer of the CaM protein. The CaM dimer 
comprises a protein Where the C-terminal end of one CaM 
molecule is attached to the N-terminal end of an adjacent 
calmodulin molecule. To construct the protein dimmer, tWo 
sets of polymerase chain reaction (PCR) reactions are per 
formed. To amplify the CaM gene, primers are designed such 
that they code for NheI and SapI endonuclease site at the 5' 
and 3' end for one CaM gene and NdeI and Nhe I site for the 
other CaM gene. As illustrated in FIG. 2, the tWo fragments 
Will be then individually ligated into plasmid pTWinl. This 
expression vector contains the sequence for the cellulose 
binding domain, Which alloWs a?inity puri?cation of the 
fusion protein. The CaM dimer is expressed and puri?ed. TWo 
types of CaM dimers Were constructed, one containing a 
unique cysteine at the C-terminus and the other containing 
tWo cysteines one at each terminus. Dimers of other proteins 
can be prepared in an analogous manner. 
Using a heterobifunctional linker containing maleimide 
and succinimide groups, an allyamine is attached to the CaM 
dimer. Similar chemistry can be performed to modify a phe 
nothiaZine derivative containing a free amino group With 
N-succinimidylacrylate. As illustrated in FIG. 3, using modi 
?ed CaM, the phenothiaZine derivative, and the acrylamide 
bisacrylamide couple, smart hydrogel polymer material can 
be synthesiZed by free radical polymerization. In the case of 
the CaM dimer With tWo cysteines, smart material can be 
synthesiZed using modi?ed CaM Without the phenothiaZine 
derivative. The hydrogel can be synthesiZed With different 
dimensions. 
CaM undergoes a hinge-type motion upon binding to cal 
cium. CaM consists of tWo domains, the N- and the C-do 
main. TWo high af?nity calcium-binding sites are located in 
the C-domain and the other tWo loW a?inity calcium-binding 
sites are located in the N-domain. As illustrated in FIG. 1, 
upon binding to calcium, CaM undergoes a change in confor 
mation, Which exposes tWo hydrophobic pockets located in 
the N- and C-domains. Certain hydrophobic peptides and the 
anti-psychotic phenothiaZine class of drugs interact With 
these exposed hydrophobic pockets. 
Like the monomeric units, the multimeric biopolymers 
change their conformation in response to the microenviron 
ment. In fact, changes in multimeric biopolymers in response 
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to a particular microenvironmental change are greater in mag 
nitude than are changes in monomeric units that comprise the 
multimeric biopolymer that are caused by the same microen 
vironmental change. For example, the conformational change 
induced in the CaM dimer is greater in magnitude than the 
conformational change induced in a separately tested, single 
CaM molecule in response to calcium binding. Such changes 
in multimeric biopolymers, therefore, can be additive or even 
greater than additive, compared to the changes in the mono 
meric units that comprise the biopolymer, in response to the 
same microenvironment. 
Multimeric Proteins and Polypeptides 
The multimeric proteins andpolypeptides comprise at least 
tWo, preferably from 2 to 10 proteins or polypeptides. At least 
one, preferably a plurality, of the monomeric units of the 
multimeric protein comprise a binding region for an analyte. 
The monomeric units of the multimeric proteins andpolypep 
tides may be the same or different. For example, the multim 
eric protein may be comprised of a single protein. Alterna 
tively, the multimeric protein may comprise a structural 
protein Which changes its conformation in response to contact 
With an analyte and an enZyme Which catalyZes a chemical 
reaction With its speci?c substrate. Catalysis of such reaction 
results in release of protons or removal protons from the 
microenvironment of the multimeric protein. 
In certain instances, the conforrnationally-reactive multi 
meric proteins are designed to undergo a change in response 
to binding of a speci?c biochemical to the binding site or sites 
in the multimeric protein. In other instances, the conforrna 
tionally-reactive multimeric proteins of the present invention 
are designed to undergo a change in conformation in response 
to a change in ion concentration, particularly a change in 
hydrogen ion or hydroxide concentration. For example, ion 
concentration changes above or beloW the isoelectric point of 
the protein Will cause the protein to change its three-dimen 
sional shape. 
The multimeric proteins may comprise a plurality of one or 
more structural proteins that undergo a conformational 
change in response to binding to an analyte. Alternatively, the 
multimeric proteins may comprise a plurality of enzymes 
linked to or in close proximity to a plurality of structural 
proteins. Upon binding to their respective substrates, the 
enZymes catalyZe a reaction that leads to a change in pH in the 
microenvironment surrounding the structural protein thereby 
causing a change in conformation of the structural proteins. 
Methods for preparing multimers of proteins are knoWn in 
the art and a variety of methods exist. In one method, sulfhy 
dryl groups present in cysteine amino acids of different pro 
teins are used to create covalent bonds betWeen the separate 
proteins. This is done through formation of disul?de bonds 
betWeen the cysteines in the different proteins. Such di sul?de 
bond formation occurs under oxidative conditions, i.e., atmo 
spheric oxygen catalyZes formation of the disul?de bonds. In 
using this method of forming protein multimers, care must be 
taken to ensure that the cysteines involved in formation of the 
disul?de bonds Will not affect the structure or function of the 
protein in an adverse Way. 
In addition to crosslinking through disul?de bond forrna 
tion, other methods of chemical crosslinking of proteins to 
one another exist. For example, this can be achieved by either 
using directly reactive groups on the protein (e. g., amines, 
carboxylic groups, etc.) or by creating reactive groups on the 
protein (e.g., in the case of glycosylated proteins the sugars 
are oxidiZed to from aldehydes, acids, etc.). Once reactive 
groups on the protein exist, then they are directly reacted With 
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the next protein or they are connected to the next protein via 
commercially available mono- or bifunctional linkers by fol 
loWing Well-established protocols. 
Other approaches to making protein multimers involve 
manipulation of the genes encoding such proteins. After 
manipulation, the genes are used to produce the proteins. 
Such proteins may be multimeric proteins or may be proteins 
that are then crosslinked to one another, as described above. 
For example, in one instance, genes encoding proteins (the 
same protein or different ones, depending on the chosen 
application) can be fused together, end-to-end or start-to-end 
from their N- and C-termini, using recombinant DNA tech 
niques. In such method, plasmids are constructed that incor 
porate the gene of the designed chosen multimer protein. The 
plasmids are inserted into bacterial, yeast, or mammalian 
vectors. The proteins are then expressed and puri?ed using 
established molecular biology protocols. 
Such recombinant DNA techniques can also be used to 
produce the monomeric subunits of What is to become the 
protein multimer. In such method, site-directed mutagenesis 
is used to remove or create unique amino acids in the protein 
monomer that facilitate attachment of one protein to another. 
Such site-directed mutagenesis techniques are Well knoWn to 
those skilled in the art. For example, such method can be used 
to introduce cysteine amino acids into the protein monomers. 
When the manipulated gene is then used to produce the pro 
teins, such proteins can then readily be crosslinked to one 
another, as described above. Such techniques are described in 
US. Pat. Nos. 4,132,746 and 4,187,852. 
Conformational changes in multimeric proteins can be 
detected using techniques such as NMR and X-ray crystal 
lography. Several biosensing systems have been developed in 
Which a ?uorophore is attached to a unique site in the protein 
(Salins, L. L. E., Schauer-Vukasinovic, V., Daunert, S. SPIE 
Int. Soc. Opt. Eng. 1998, 3115 16-24; Schauer-Vukasinovic, 
V. Cullen, L., Daunert, S. J Am. Chem. Soc., 1997, 119, 
11102-11103; Wenner, B. R. Douglass, P. M., Shrestha, S., 
Sharma, B. V., Lai, S., Madou, M. 1., Daunert, S. Proceedings 
of SPIE, 2, 59-70, 2001; L. L. E. Salins, C. Mark Ensor, R. 
Ware, and S. Daunert, Anal. Biochem., in press, 2001). The 
change in conformation in the presence of a ligand is then 
monitored by measuring a change in ?uorescence of the 
reporter ?uorophore. 
The multimeric proteins are dimers, trimers, and multimers 
of the same protein or of combinations of tWo or more differ 
ent proteins forming a polymer. The genetically engineered 
polymer proteins can be used as sensors/ actuators in a variety 
of applications that range from biosensors to responsive drug 
delivery systems to molecular machines. Therefore, We envi 
sion applications in environmental analysis, and in the diag 
nostics, biotechnology, and pharmaceutical industries. 
Multimeric Nucleic Acids 
The multimeric biopolymers can also be nucleic acid mol 
ecules, such as DNA or RNA. As for multimeric proteins, 
described above, the nucleic acid multimers comprise repeat 
ing units of tWo or more smaller, monomeric molecules. Such 
monomeric units may be the same or different. Such mono 
mers, as Well as the multimeric nucleic acid, are able to 
respond to the presence of an analyte. 
One such type of nucleic acid monomer that can be used to 
make multimeric nucleic acids is called an oligonucleotide 
ligand or “aptamer.” Aptamers are single-stranded DNA or 
RNA molecules that bind With high a?inity to speci?c target 
or analyte molecules. Such analyte molecules can be drugs, 
vitamins, hormones, antibodies, enZymes, co-factors, nucle 
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otides, proteins and so forth. Aptamers can range from 
between 8 to 120 or more nucleotides in length. Within this 
nucleotide sequence is contained a minimal sequence needed 
for binding to the analyte. Such sequence is normally between 
15 to 50 nucleotides in length. Aptamers undergo a confor 
mational change after binding of speci?c analytes. The bind 
ing constant of aptamers to their speci?c analyte molecules 
ranges from micromolar to sub-nanomolar ranges. 
Aptamers have a number of advantages over other mol 
ecules that speci?cally bind target molecules. Aptamers have 
remarkable speci?city for their speci?c analytes. Aptamers 
can discriminate betWeen analytes based on subtle differ 
ences in the analytes. For example, aptamers can discriminate 
betWeen analytes based on the presence or absence of a 
methyl or hydroxyl group. Aptamers can discriminate 
betWeen analytes based on the difference betWeen the D- and 
L-enantiomer. 
Another advantage of aptamers is that their synthesis is 
straightforward. Aptamers are produced by chemical synthe 
sis, Which is extremely accurate and reproducible. Aptamers 
produced by such synthesis can be puri?ed, under denaturing 
conditions, to a high degree. Reporter molecules, ?uoro 
phores for example, can subsequently be easily attached to 
puri?ed aptamers. Such attached ?uorophores can emit a 
?uorescence signal Whose intensity varies depending on 
Whether the aptamer has or has not bound its target analyte. 
Such differential emission of ?uorescence in response to 
target binding can facilitate the use of such labeled aptamers 
as sensors and actuators. 
Aptamers that bind selectively to a speci?c analyte are 
commonly selected from very large random sequence oligo 
nucleotide libraries comprised of as many as 1015 random 
sequences (McGoWn, et al., l995,Anal Chem, 67: 663A-68A; 
Jayasena, 1999, Clin Chem, 45:1628-50). Such selection 
involves an iterative enrichment process. Such process is 
called SELEX (systematic evolution of ligands by exponen 
tial enrichment). Steps in the SELEX process involve passing 
the entire oligonucleotide library over a support, such as an 
a?inity column, to Which the analyte molecule is attached. 
The oligonucleotides that do not bind to the analyte in the 
column pass through the column and are discarded. The oli 
gonucleotides that bind to the analyte are then eluted from the 
column. The oligonucleotides that elute from the column are 
then ampli?ed using the PCR. The PCR-ampli?ed pool of 
oligonucleotides is then passed over the column again, as 
described above, and the eluate is again ampli?ed by PCR. 
The cycle is repeated numerous times. Commonly, the cycle 
is repeated anyWhere from betWeen 8 to 15 times. 
Once aptamers are obtained, polymers of the aptamers are 
prepared. Such polymeric aptamers can be prepared by 
employing several strategies. For example, DNA synthesiZers 
can be used to prepare a DNA segment that terminates in a 
functional chemical group (e.g., thiol, biotin, etc.). This 
alloWs for coupling of the DNA aptamer unit to form dimers, 
trimers, etc. of the original aptamer. 
In another embodiment, the conformationally reactive 
multimeric biopolymers are aptamers, Which are nucleic acid 
ligands composed of single strands of DNA or RNA. These 
are molecular recognition elements that upon binding to their 
respective ligands (e.g., drugs, vitamins, hormones, antibod 
ies, enzymes, biological co-factors, etc.) undergo a confor 
mational change. The binding constant of aptamers to their 
respective ligands ranges from uM to sub-nM, making them 
suitable for detection of biomolecules in biological ?uids. 
The three-dimensional structure of a functional aptamer can 
be denaturated by temperature, pH, salt gradient, metal ions, 
and electrochemical potential. Thus, aptamers can be used in 
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a similar fashion to the binding proteins mentioned above. 
Speci?cally, polymeric aptamers can be prepared by employ 
ing several strategies. For example, DNA synthesiZers can be 
used to prepare a DNA segment that terminates in a functional 
chemical group (e.g., thiol, biotin, etc.). This alloWs for cou 
pling of the DNA aptamer unit to form dimers, trimers, etc. of 
the original aptamer. Thiol-terminated aptamers can be 
coupled to each other by formation of disul?de bonds (con 
necting unit betWeen tWo aptamers) under oxidiZing condi 
tions. In the case of biotin-terminated aptamers the connect 
ing units can be avidin, streptavidin, or anti -biotin antibodies, 
for example. Avidin or streptavidin bind to up to four bioti 
nylated compounds, Which alloWs for organiZation of the 
aptamers in netWorks that are three-dimensionally different 
from those assembled by employing antibodies as connec 
tors. Polymeric RNA aptamers can be prepared in a similar 
fashion. 
Redox Polymers 
The multimeric biopolymers are useful if the changes (e. g., 
conformational change) that they undergo in response to the 
microenvironment (e. g., binding of an analyte) are reversible. 
Reversibility alloWs the inventions of Which the multimeric 
biopolymers are a component to be used more than once. That 
is, once the multimeric biopolymer binds its speci?c analyte 
and, for example, causes sWelling and shrinking of a hydro 
gel, it Would be advantageous if the multimeric biopolymer 
could be returned to its original state, for example the state in 
Which no analyte is bound by the multimeric biopolymer. 
One Way in Which the changes the multimeric biopolymers 
undergo can be reversed is through the use of redox polymers. 
Redox polymers are polymers, such as polypyrrole, polya 
niline, polythiophene and the like, that are sensitive to pH, 
applied potential and chemical potential in their microenvi 
ronment. The redox polymers are electronically conducting 
polymers. Such redox polymers, can conduct a current that 
originates from an electrode, for example, and When the redox 
polymer is in contact or close proximity to the multimeric 
biopolymers, can reverse the changes that occurred in the 
multimeric biopolymer, by analyte binding, for example. In 
such case, the invention can be vieWed as a “molecular gate” 
Wherein the multimeric biopolymer opens or closes in 
response to analyte binding and Wherein the redox polymer 
acts to override this process. 
The Redox polymer device Which employs the multimeric 
biopolymer can be used as a molecular gate or actuator to 
regulate the ?oW of molecules, such as drugs, heparin, bio 
activators, and ions through a channel or an opening in the 
device. 
An example of the manner in Which conformational 
changes of multimeric biopolymers may be utiliZed in con 
junction With MEMS and NEMS is that of the incorporation 
of the multimeric biopolymers Within channels of a substrate. 
These channels could, for example, be connected to a drug 
delivery chamber on one side. Opening and closing of the 
channels is accomplished by changing the conformation of 
the multimeric polymers. For example, in those cases Where 
the biopolymer contains ligand-binding proteins (examples 
include binding proteins, receptors, enZymes, etc.), the con 
formational change occurs When the ligand binds to the pro 
tein. 
The multimeric biopolymer may be attached to the channel 
surface, for example by a covalent bond. Alternatively, the 
multimeric biopolymer may be in a solution or suspension 
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Which is disposed Within the porous substrate. Depending on 
the conformation of the biopolymer, the pores Will be open or 
closed. 
The device may be a MEMS or NEMS structure. Such 
structures are top -doWn machined devices With dimensions in 
the micrometer respectively nanometer range. They typically 
involve semiconductor industry type manufacturing meth 
ods. Products include pressure sensors, valves, pumps, accel 
erometers, gyros, etc. With the ever decreasing dimensions of 
the lithography Written features there is noW an overlap 
betWeen features that can be made With top-doWn methods 
and bottom-up methods (the ones described above to make 
the multimeric biopolymer sensors/ actuators). This siZe over 
lap presents many neW product opportunities. For example 
MEMS and NEMS structures may be manipulated by multi 
meric biopolymers. In such an embodiment, the multimeric 
biopolymer directly opens and closes the channel. 
In a further embodiment the multimeric biopolymer is 
attached to or in communication With a movable door that is 
comprised of a rigid substance, such as for example silicon, or 
a hydrogel. The change in conformation that is initiated by 
binding of the analyte to the multimeric biopolymer causes 
the door to move, thereby opening or closing the channel. 
Such devices may further comprise a redox polymer Which is 
blended With the multimeric biopolymer as described beloW. 
Once the polymer proteins are prepared, they preferably 
are coupled to the surface of the substrate. As is the case With 
the attachment of oligonucleotides to these surfaces, there are 
numerous Well-established protocols for the successful 
attachment of proteins to surfaces. To limit loss of function or 
collapse of the three-dimensional structure of the multimeric 
biopolymer, hydrophilic surfaces are chosen. 
Direct immobilization of the multimeric protein to the 
surface can be attained by reacting an amino acid on the 
protein With the surface itself or by disposing a coating With 
reactive groups on the channel surface. Different amino acids 
in a protein biopolymer structure are used for covalent attach 
ment. For example, the most common method of attachment 
of proteins to surfaces is through the amine groups of lysine 
residues. The thiol groups of cysteine molecules, as Well as 
the carboxylic groups of aspartic acid and glutamic acid are 
also employed. The surface of the substrate usually contains 
groups that are reactive and can directly be used for attach 
ment to the multimeric biopolymer. In some cases, hoWever, 
the surface of the substrate needs to be activated to introduce 
reactive groups for attachment. A number of surface modify 
ing reactions are commonly employed, and include the use of 
diaZo, glutaraldehyde, cyanogen bromide, carbodiimide, 
epoxide, and 2-?uoro-l-methylpyridinium tosylate. Upon 
activation of the substrate surface, the multimeric biopolymer 
is then directly attached through the amine, thiol, or carboxy 
lic groups present in the multimeric biopolymer. Addition 
ally, multimeric biopolymers polymer may be attached to the 
substrate by introducing complementary af?nity pairs into 
both polymers. For example, the biotin/streptavidin system 
mentioned in the case of the immobiliZation of the oligo 
nucleotides to the redox surface is also employed here. Biotin 
and streptavidin can be attached to the multimer and substrate 
by Well-established chemical/biochemical protocols. The 
biotin/streptavidin system is not the only one suitable for this 
type of attachment, and other types of af?nity pairs can also 
be employed. 
The polymeric aptamers can also be attached to a surface of 
the substrate by one of the many methods found in the litera 
ture to attach nucleic acids. 
When the multimeric biopolymer is blended or attached to 
a redox polymer Which is in electrical contact With a conduc 
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tor, eg a metal or carbon electrode, the protons generated at 
the redox polymer through electrochemical action are 
released closer to the multimeric biopolymer to affect the 
three-dimensional structure thereof. Generally speaking, it is 
preferable to have more than one means of controlling the 
actions of a device. This is especially true in the case of 
medical devices, Where the need to ensure safety and e?icacy 
inevitable requires some backup control system that is exter 
nally accessible and able to override the chemical control 
system if the device is not functioning properly or its actions 
are no longer appropriate to the needs of the patient. Such a 
backup system for the present devices may be illustrated 
through the rigid channel example, With the addition of an 
element of electronic control through use of redox polymer. 
The main bene?t of this approach is the ability to use the 
external electrochemical potential to override the chemical 
actuation. The overriding can result in either a permanent 
change in the structure of the multimeric biopolymer (desir 
able in cases Where the system needs to be shut off, for 
example When a device begins to fail), or in a reversible 
change of the three-dimensional structure of the multimeric 
biopolymer. The latter is important When a binding event 
needs to be reversed for resetting the device. An additional 
bene?t of the “Wired” system is the speed by Which this 
electrochemically-induced changes can be imposed on the 
multimeric biopolymer/redox polymer blend. 
The electronic backbone is typically a redox polymer such 
as polypyrrole, polyaniline, polythiophene, etc. The redox 
polymer may be deposited by electrodeposition from a solu 
tion comprising the precursors thereof onto a conductor sur 
face such as a patterned metal electrode thereby con?ning the 
actuator onto the conductive parts of a MEMS or NEMS 
structure only. The multimeric biopolymer may be litho 
graphically patterned silk screened or drop delivered onto the 
metal electrode. Preferably, the device further comprises a 
small battery, a microprocessor (ideally incorporating telem 
etry), and a storage chamber for holding substance Which is 
dispensed When an analyte binds to the multimeric biopoly 
mer. For devices Which are used to deliver therapeutic com 
pounds such as for example a drug, it is preferred that the 
device be implantable and be comprised or coated With a 
biocompatible substance. 
The device can further comprises an override system Which 
comprises a hydrogel/redox polymer blend instead of just a 
redox polymer. This alloWs coupling of the binding event 
With sWelling/ shrinking of the hydrogel While maintaining 
the override of the chemical actuation by an external chemical 
potential. The redox polymer may be seen as a conductive 
electrode extending throughout the hydro gel. The major ben 
e?t is that ionic changes induced by a potential change on the 
metal electrode are noW distributed throughout the hydrogel 
making for a faster response of this mixed conductor system. 
The mechanism of sWelling and shrinking remains the same 
as With the hydro gel on a metal electrode except that the effect 
is faster and can permeate through a thicker layer of hydro gel. 
Moreover the effect is not necessarily based on a pH change. 
For example, the effect may be based on Water uptake by the 
hydrogel. 
The redox polymer can be electrodeposited on the conduc 
tor With the gel ?lm already in place. A hydro gel is permeable 
to the monomers of a redox polymer so the hydrogel may be 
placed over the metal electrode and With the electrode biased 
properly the monomer polymeriZes Within the overlaying 
hydro gel . Alternatively the hydrogel and the redox monomers 
may be mixed beforehand and polymeriZed in situ on the 
metal electrode. The redox-polymer/ hydro gel blend may 
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then be further modi?ed chemically by incorporating a mul 
timeric biopolymer using any of the chemical attachment 
schemes discussed above. 
Hydrogels 
Hydro gels of the present invention exhibit dramatic effects 
of swelling and shrinking upon a stimulus. One such stimulus 
is movement or conformational change of the multimeric 
biopolymers. Another type of stimulus occurs When there is a 
change in pH in the environment in Which the hydrogel is 
present. Such local pH change causes Water and counter-ions 
to move in or out of the hydrogel and this induces sWelling or 
shrinking of the hydrogel. This process is illustrated in FIG. 4, 
Where a metal electrode underneath a hydrogel, causes 
hydrolysis and a local pH change. 
Certain types of hydrogels undergo abrupt changes in vol 
ume in response to changes in pH, temperature, electric ?elds, 
saccharides, antigens and solvent composition. Natural and 
arti?cial hydrogels may also be forced to shrink or sWell by 
applying a bias on a metal electrode underneath or embedded 
in a hydrogel gel. The process is illustrated in FIG. 4 for the 
case of a hydrogel on top of a Pt electrode. The hydrolysis 
process creates a local pH change, Which changes the volume 
of the hydrogel. In this case, the hydrogel acts an ionic type 
actuator, i.e., the polymer does not conduct electrons and 
actuation is induced by ion migration (someWhat similar to 
the Way an action potential in a nerve cell is generated). The 
local pH change leads to a different charge on the polymer 
backbone and this causes Water and counter-ions to move in 
or out of the hydrogel bulk and this, in turn, induces sWelling 
or shrinking of the hydrogel. Depending on the type of hydro 
gel, a pH increase or pH decrease may induce the hydrogel 
volume changes. With the metal electrode used as an anode 
the pH decreases, and With the electrode used as a cathode the 
pH increases. This sWelling behavior is governed by the 
amount of cross-linking of the hydrogel and the a?inity of the 
polymer chains for solvent. 
A hydrogel can be prepared using any suitable monomer 
that, When polymerized, forms a hydrogel. Such monomers 
include, but are not limited to, acrylates, acrylamides, 
acetates, acrylic acids, vinyl alcohols, and glycols. A hydro 
gel made from an acrylamide can be prepared by combining 
speci?c volumes of a ?ltered 40 Wt % acrylamide solution, a 
0.1 -10 Wt % N,N-methylenebisacrylamide solution, and a 98 
Wt % 2-(dimethylamino) ethyl methacrylated (DMAEMA) 
solution. The mixture may be deoxygenated by bubbling N2 
through the mixture for 15 minutes. A volume of 10-20 ML of 
a 10 Wt % potassium persulfate solution may then be added to 
initiate the polymerization reaction. A hydrogel can be made 
from a hydroxyethyl methacrylate (HEMA). A HEMA based 
hydrogel may be a copolymer of HEMA and methyl 
methacrylate (MMA) and may be prepared by combining a 
co-monomer feed of 75 mol % HEMA and 25 mol % MMA, 
With 1 mol % ethylene glycol dimethacrylate (EGDMA) as 
the cross-linking agent and a trace amount of dimethoxy 
phenyl acetophenone (DMPA) as the photoinitiator. The 
polymerizations are carried out at ambient conditions. Three 
different compositions of a HEMA-DMAEMA copolymer 
may be prepared. The ?rst may consist of 0.198 HEMA, 
0.0494 DMAEMA, and 0.0752 H2O. The second may be 
composed of 0.198 HEMA, 0.0494 DMAEMA, 0.00220 
EGDMA, 0.450 H20 and 0.300 ethylene glycol. The compo 
sitions above are all in volume fractions. The third PHEMA 
DMAEMA composition may be 76 Wt % HEMA, 10 Wt % 
DMAEMA, 2 Wt % EGDMA, 12 Wt % H20 and a trace 
amount of DMPA. 
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Hydrogels can be placed in close proximity to the multim 
eric biopolymers, or can be blended With multimeric biopoly 
mers, in such a Way that the stimulus for sWelling or shrinking 
of the hydrogel is provided by the associated multimeric 
biopolymer When suchbiopolymerbinds to a speci?c analyte. 
The stimulus that causes sWelling or shrinking of the hydro 
gel can be the movement or conformational changes that 
occurs in the multimeric biopolymer. In this case, the multi 
meric biopolymer directly causes the sWelling or shrinking of 
the hydro gel. 
The binding of an analyte by the multimeric biopolymer 
can also result in release or consumption of protons. Such 
protons can cause a local change in the pH and can cause 
sWelling or shrinking of the hydrogel due to movement of 
Water and counter-ions into or out of the hydrogel, as 
described above. 
The present invention is directed to stimuli-responsive 
hydrogel is prepared by combining a biopolymer having a 
biomolecule ligand With a monomer capable of forming a 
hydrogel to form a mixture Which is then polymerized to form 
a porous hydrogel netWork that integrates the biological rec 
ognition element Within the hydro gel netWork. The biological 
recognition element is a binding protein. For example, the 
integration of calmodulin (CaM) and its ligand such as a 
phenothiazine derivative, Within a porous hydrogel netWork 
causes the hydrogel to undergo a phase transition in the pres 
ence of free ligand. This phase transition creates a sWelling of 
the hydrogel netWork that can be used to trigger the release of 
the phenothiazine through microactuation or for high 
throughput drug screening. CaM has four Ca++ ligand bind 
ing sites in its structure and is a calcium binding protein that 
undergoes a large conformational change upon binding cal 
cium, certain peptides, and the phenothiazine class of drugs. 
Genetically modi?ed CaM monomers have been immobi 
lized in conjunction With phenothiazine derivatives Within an 
acrylamide polymer netWork. The volume of the hydrogel 
changes When the non-covalent crosslinking betWeen the 
CaM and phenothiazine is released due to competitive bind 
ing of free chlorpromazine (CPZ) in the binding sites on 
CaM. The observed hydrogel microdome sWelling correlates 
to the amount of free analyte ligand and can be used in 
developing 1-D and 2-D microdome sensor arrays for high 
throughput screening of pharmaceuticals. 
CaM is genetically engineered to contain a unique cysteine 
at the C-terminus in order to achieve oriented immobilization 
Within the polymer netWork of the hydrogel. CaM undergoes 
a large conformational change upon binding calcium and 
With biomolecules such as peptides and the phenothiazine 
family of drugs, i.e., chlorpromazine, thioridazine, tri?uop 
erazine and perphenazine. 
CaM undergoes three conformational changes as illus 
trated in FIGS. 5(a) to 5(0). The ?rst change is in the presence 
Ca++. In this conformation, CaM has “dumbbell” conforma 
tion (FIG. 5(a)). When CaM is bound to phenothiazine, a 
contrictive conformation (FIG. 5(b)) is formed. When Ca++ is 
removed from CaM using ethylene glycol-bis([3-aminoethyl 
ether)-N',N',N',N'-tetraacetic acid (EGTA), the protein 
changes from its bound conformation to its native conforma 
tion (FIG. 5(0)) and the hydrogel sWells and the phenothiaz 
ine is released. The hydrogel of the invention can be used as 
a biosensor to sense the presence of an analyte, as an actuator 
to actuate a mechanical response When exposed to an analyte 
to cause release of a ligand bound to CaM, or to perform both 
functions, or as a high-throughput screening device. 
To integrate a protein such as CaM into the hydrogel net 
Work, as described above, the protein is genetically engi 
neered to contain a single cysteine at the C-terminus that 





